博瑞医药：在代谢药领域定位中国药企新坐标

Core Viewpoint - The company, Borui Pharmaceutical, is transitioning from a focus on high-end raw materials and generic drugs to innovative drug development, aiming to meet unmet clinical needs and establish itself as a leader in the competitive global metabolic drug market [3][4]. Group 1: Company Transformation and Strategy - Borui Pharmaceutical's listing on the STAR Market has significantly enhanced its risk resistance and provided the confidence to invest in high-risk, long-cycle original drug research and development [4]. - The company emphasizes a strategy of pursuing "difficult yet correct" projects, focusing on innovative drugs that address unmet clinical needs [3][6]. - The company has successfully leveraged its expertise in raw materials and generic drugs to support its innovative drug development, creating a unique technological "moat" [4][5]. Group 2: Research and Development Investment - In the first three quarters of 2025, Borui Pharmaceutical's R&D investment reached 470 million yuan, a year-on-year increase of 112.17%, with R&D expenses accounting for 53.79% of revenue [5]. - The company holds 283 valid patents, including 231 invention patents, with a patent layout covering multiple countries, laying a solid foundation for its global innovative drug strategy [5]. Group 3: Innovative Drug Pipeline - Borui Pharmaceutical is developing a differentiated product pipeline in the weight loss drug sector, focusing on multi-target collaboration and innovative delivery methods to address industry pain points [6][8]. - The innovative drug BGM0504, targeting type 2 diabetes and weight loss, has completed all patient enrollments in its domestic phase III clinical trial and is in the dosing and follow-up stage [6][9]. - The company is also advancing the development of oral formulations to improve patient compliance, addressing the low adherence rates associated with injectable weight loss medications [6][7]. Group 4: Production and Commercialization Capabilities - Borui Pharmaceutical is building a comprehensive capability from R&D to commercialization, with production bases established in Suzhou and Taixing for the development and production of BGM0504 [9]. - The company has formed a partnership with China Resources Sanjiu to accelerate the R&D and commercialization of BGM0504, leveraging their distribution capabilities to expand into serious medical markets [9]. - Borui Pharmaceutical's global competitiveness is underscored by its innovative drug pipelines, which are positioned to lead in the global market, with ongoing clinical trials in the U.S. and Indonesia [9].